IL165285A0 - Compositions and methods for treating diabetes - Google Patents

Compositions and methods for treating diabetes

Info

Publication number: IL165285A0
Authority: IL; Israel
Prior art keywords: compositions; methods; treating diabetes; gastrin; treating
Prior art date: 2002-06-07

Application number

IL16528503A

Other languages

English (en)

Original Assignee

Waratah Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-07

Filing date

2003-06-09

Publication date

2005-12-18

2003-06-09 Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc

2005-12-18 Publication of IL165285A0 publication Critical patent/IL165285A0/xx

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 2
108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
102100021022 Gastrin Human genes 0.000 abstract 1
102000052874 Gastrin receptors Human genes 0.000 abstract 1
108010052343 Gastrins Proteins 0.000 abstract 1
230000008629 immune suppression Effects 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
230000001861 immunosuppressant effect Effects 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000009707 neogenesis Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL16528503A 2002-06-07 2003-06-09 Compositions and methods for treating diabetes IL165285A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38703202P	2002-06-07	2002-06-07
US43059002P	2002-12-03	2002-12-03
PCT/US2003/018377 WO2003103701A1 (en)	2002-06-07	2003-06-09	Compositions and methods for treating diabetes

Publications (1)

Publication Number	Publication Date
IL165285A0 true IL165285A0 (en)	2005-12-18

Family

ID=29739925

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16528503A IL165285A0 (en)	2002-06-07	2003-06-09	Compositions and methods for treating diabetes
IL165285A IL165285A (en)	2002-06-07	2004-11-18	Compositions for treating diabetes, kits comprising such compositions and other uses

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL165285A IL165285A (en)	2002-06-07	2004-11-18	Compositions for treating diabetes, kits comprising such compositions and other uses

Country Status (12)

Country	Link
US (3)	US20040023885A1 (de)
EP (1)	EP1511509B1 (de)
JP (1)	JP2005533775A (de)
KR (1)	KR20050048542A (de)
CN (1)	CN1671407B (de)
AT (2)	ATE445407T1 (de)
AU (1)	AU2003243501A1 (de)
CA (1)	CA2486584A1 (de)
DE (2)	DE60316798T2 (de)
ES (1)	ES2334268T3 (de)
IL (2)	IL165285A0 (de)
WO (1)	WO2003103701A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6558952B1 (en) *	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
JP2004520345A (ja)	2001-01-12	2004-07-08	ワラター・ファーマシューティカルズ・インク	糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
US7037504B2 (en) *	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
US20060234373A1 (en) *	2002-05-24	2006-10-19	Alex Rabinovitch	Treatment for diabetes
EP1837031B1 (de) *	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
US20040023885A1 (en)	2002-06-07	2004-02-05	Brand Stephen J	Compositions and methods for treating diabetes
US20040229810A1 (en) *	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
EP1615640B1 (de) *	2003-04-22	2007-01-24	Wyeth	Antineoplastische zusammensetzungen
US20080039379A1 (en) *	2003-05-27	2008-02-14	Waratah Pharmaceuticals, Inc.	Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US20090202494A1 (en) *	2004-01-30	2009-08-13	Antonio Cruz	Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2006002532A1 (en) *	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
US8268791B2 (en) *	2004-08-25	2012-09-18	Aegis Therapeutics, Llc.	Alkylglycoside compositions for drug administration
US9895444B2 (en)	2004-08-25	2018-02-20	Aegis Therapeutics, Llc	Compositions for drug administration
US20060046962A1 (en)	2004-08-25	2006-03-02	Aegis Therapeutics Llc	Absorption enhancers for drug administration
US20140162965A1 (en)	2004-08-25	2014-06-12	Aegis Therapeutics, Inc.	Compositions for oral drug administration
BRPI0519646A2 (pt) *	2004-12-30	2009-07-14	Hills Pet Nutrition Inc	composição, processo para preparar uma composição de ração para felino baseada em carne e carboidrato, produto, método para prevenir ou tratar diabetes em um felino suscetìvel a ou sofrendo de diabetes, kit adequado para prevenir ou tratar diabetes, meio, uso de uma composição, e, processo para preparar uma composição baseada em carne e carboidrato para consumo por um felino
CN101365476A (zh) *	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
US10137083B2 (en) *	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
US11311477B2 (en) *	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US7998927B2 (en) *	2006-06-23	2011-08-16	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) *	2006-06-23	2009-12-31	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) *	2006-06-23	2012-05-08	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) *	2006-06-23	2008-09-16	Aegis Therapeutics, Inc.	Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) *	2006-06-23	2012-07-24	Aegis Therapeutics Llc	Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) *	2006-06-23	2011-12-27	Aegis Therapeutics, Llc	Stabilizing alkylglycoside compositions and methods thereof
WO2008007933A1 (en) *	2006-07-14	2008-01-17	Postech Academy-Industry Foundation	Epidermal growth factor increasing insulin secretion and lowering blood glucose
CA2756690C (en)	2008-03-28	2016-08-16	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
US20110212052A1 (en) *	2008-07-25	2011-09-01	The Johns Hopkins University	Methods and compositions of treating and preventing autoimmune diseases
US8440631B2 (en)	2008-12-22	2013-05-14	Aegis Therapeutics, Llc	Compositions for drug administration
WO2010081015A1 (en) *	2009-01-09	2010-07-15	The Regents Of The University Of California	Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening
EP4085899A1 (de)	2011-06-14	2022-11-09	Neurelis, Inc.	Verabreichung von benzodiazepin
AU2012289921B2 (en) *	2011-08-03	2017-05-04	Revivallon Biopharmaceutical Co., Ltd	Treatment of type 2 diabetes with FTY720
US20130273089A1 (en)	2011-11-03	2013-10-17	Tolera Therapeutics, Inc.	Antibody and methods for selective inhibition of t-cell responses
CA2853687A1 (en)	2011-11-03	2013-05-10	Tolera Therapeutics, Inc	Antibody and methods for selective inhibition of t-cell responses
WO2014138003A1 (en) *	2013-03-04	2014-09-12	Neuralstem, Inc.	Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders
WO2017083555A1 (en)	2015-11-10	2017-05-18	City Of Hope	Conditioning regimens and methods for inducing mixed chimerism
WO2017116569A1 (en) *	2015-12-31	2017-07-06	City Of Hope	Methods for treating diabetes
WO2019005871A1 (en) *	2017-06-26	2019-01-03	City Of Hope	METHODS FOR CULTURE OF CELLS OF THE ISLANDS OF LANGERHANS
IL280198B2 (en) *	2018-07-18	2026-01-01	Regenxbio Inc	Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
IL288024B2 (en)	2019-05-14	2025-12-01	Provention Bio Inc	Methods and compositions for preventing type
AU2021287998B2 (en)	2020-06-11	2026-03-12	Benaroya Research Institute At Virginia Mason	Methods and compositions for preventing type 1 diabetes
AU2022283271A1 (en)	2021-05-24	2023-12-07	Provention Bio, Inc.	Methods for treating type 1 diabetes
CA3241242A1 (en) *	2021-06-10	2022-12-15	Fouad Kandeel	Compositions and methods for islet cell transplants

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL101353A0 (en)	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
DK36392D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
US6558952B1 (en)	1992-12-14	2003-05-06	Waratah Pharmaceuticals, Inc.	Treatment for diabetes
US5885956A (en)	1992-12-14	1999-03-23	Research Triangle Pharmaceuticals	Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
CA2182034C (en) *	1994-01-24	2009-04-21	Ronald V. Nardi	Treatment for juvenile diabetes
US5624895A (en) *	1994-02-18	1997-04-29	Georgetown University Medical Center	Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US20040037818A1 (en)	1998-07-30	2004-02-26	Brand Stephen J.	Treatment for diabetes
EP1100530B1 (de)	1998-07-31	2003-10-08	Novo Nordisk A/S	In-vitro stimulation von beta zellen vermehrung
US6610535B1 (en)	2000-02-10	2003-08-26	Es Cell International Pte Ltd.	Progenitor cells and methods and uses related thereto
DK1283735T4 (da)	2000-03-31	2013-02-04	Royalty Pharma Collection Trust	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
JP2004520345A (ja) *	2001-01-12	2004-07-08	ワラター・ファーマシューティカルズ・インク	糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
US7037504B2 (en)	2001-10-23	2006-05-02	Waratah Pharmaceuticals, Inc.	Epidermal growth factor protein and gene, and methods of use therefor
US20060234373A1 (en)	2002-05-24	2006-10-19	Alex Rabinovitch	Treatment for diabetes
US20040023885A1 (en)	2002-06-07	2004-02-05	Brand Stephen J	Compositions and methods for treating diabetes
EP1837031B1 (de)	2002-06-07	2009-10-14	Waratah Pharmaceuticals, Inc.	Methoden und Kompositionen um Diabetes zu behandeln
EP1569680B1 (de)	2002-10-22	2009-01-21	Waratah Pharmaceuticals, Inc.	Behandlung von diabetes.
US20040229810A1 (en)	2002-10-22	2004-11-18	Antonio Cruz	Gastrin compositions and formulations, and methods of use and preparation
CA2522895A1 (en)	2003-04-30	2004-11-11	Waratah Pharmaceuticals, Inc.	Combined use of keratinocyte growth factor agonists and gastrin compounds
AU2004243541A1 (en)	2003-05-27	2004-12-09	Waratah Pharmaceuticals, Inc.	Compositions comprising gastrin compounds and their use in diabetes
US20090202494A1 (en)	2004-01-30	2009-08-13	Antonio Cruz	Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2006002532A1 (en)	2004-07-01	2006-01-12	Waratah Pharmaceuticals, Inc.	Methods and compositions using cd3 agonists
CN101365476A (zh)	2005-10-07	2009-02-11	瓦拉塔药品公司	Dpp-iv抑制剂和胃泌素化合物的联合使用
EP1971363A1 (de)	2005-12-02	2008-09-24	Waratah Pharmaceuticals, Inc.	Kombinationsbehandlungen mit gastrin-agonisten für diabetes und verwandten erkrankungen
WO2007095737A1 (en)	2006-02-21	2007-08-30	Waratah Pharmaceuticals Inc.	Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

2003
- 2003-06-09 US US10/457,126 patent/US20040023885A1/en not_active Abandoned
- 2003-06-09 AT AT07010865T patent/ATE445407T1/de not_active IP Right Cessation
- 2003-06-09 KR KR1020047019788A patent/KR20050048542A/ko not_active Ceased
- 2003-06-09 AT AT03757483T patent/ATE375166T1/de not_active IP Right Cessation
- 2003-06-09 ES ES07010865T patent/ES2334268T3/es not_active Expired - Lifetime
- 2003-06-09 WO PCT/US2003/018377 patent/WO2003103701A1/en not_active Ceased
- 2003-06-09 EP EP03757483A patent/EP1511509B1/de not_active Expired - Lifetime
- 2003-06-09 CN CN038185261A patent/CN1671407B/zh not_active Expired - Fee Related
- 2003-06-09 US US10/517,135 patent/US7560425B2/en not_active Expired - Fee Related
- 2003-06-09 CA CA002486584A patent/CA2486584A1/en not_active Abandoned
- 2003-06-09 AU AU2003243501A patent/AU2003243501A1/en not_active Abandoned
- 2003-06-09 DE DE60316798T patent/DE60316798T2/de not_active Expired - Lifetime
- 2003-06-09 DE DE60329724T patent/DE60329724D1/de not_active Expired - Lifetime
- 2003-06-09 IL IL16528503A patent/IL165285A0/xx unknown
- 2003-06-09 JP JP2004510820A patent/JP2005533775A/ja active Pending
2004
- 2004-11-18 IL IL165285A patent/IL165285A/en not_active IP Right Cessation
2009
- 2009-04-08 US US12/420,212 patent/US20090269337A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7560425B2 (en)	2009-07-14
US20060183674A1 (en)	2006-08-17
EP1511509A4 (de)	2005-04-27
CN1671407A (zh)	2005-09-21
US20090269337A1 (en)	2009-10-29
AU2003243501A1 (en)	2003-12-22
KR20050048542A (ko)	2005-05-24
ATE445407T1 (de)	2009-10-15
EP1511509B1 (de)	2007-10-10
CA2486584A1 (en)	2003-12-18
US20040023885A1 (en)	2004-02-05
DE60329724D1 (de)	2009-11-26
WO2003103701A1 (en)	2003-12-18
IL165285A (en)	2010-04-29
ES2334268T3 (es)	2010-03-08
JP2005533775A (ja)	2005-11-10
DE60316798T2 (de)	2008-07-24
EP1511509A1 (de)	2005-03-09
DE60316798D1 (de)	2007-11-22
CN1671407B (zh)	2010-05-26
ATE375166T1 (de)	2007-10-15

Publication	Publication Date	Title
IL165285A0 (en)	2005-12-18	Compositions and methods for treating diabetes
WO2004037195A3 (en)	2005-06-16	Treatment of diabetes
IL156828A0 (en)	2004-02-08	Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
MX2007006830A (es)	2008-02-07	Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
CA101579S (en)	2004-06-02	Keypad for a handset
NO20013451L (no)	2001-07-12	1-Heterocyklus-substituerte diarylaminer
CA102338S (en)	2005-06-06	Keypad for a handset
CA102893S (en)	2005-04-27	Keypad for a handset
CA119300S (en)	2007-12-05	Handset
JO2464B1 (en)	2009-01-20	Formulas contain actinacidine and binary sugars
MXPA05010582A (es)	2005-11-23	Combinaciones antineoplasicas.
CA102464S (en)	2005-04-20	Keypad for a handset
TNSN05046A1 (en)	2007-05-14	Method of preparing dry powder inhalation compositions
CA102330S (en)	2004-08-31	Front cover for a handset
AU2003297318A1 (en)	2004-07-22	Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TW200616639A (en)	2006-06-01	Methods for treating a mammal before, during and after cardiac arrest
CA102901S (en)	2005-04-27	Front cover for a handset
CA102196S (en)	2004-02-18	Keypad for a handset
EP1511506A4 (de)	2006-12-06	Zusammensetzungen und verfahren zur prävention, behandlung und diagnose von diabetes
CA102846S (en)	2005-04-27	Front cover for a handset
CA102847S (en)	2005-04-27	Combined keypad and frame for handset
WO2004035033A3 (en)	2004-07-22	Clofarabine and camptothecin chemotherapy combination
CA102197S (en)	2004-02-18	Front cover for a handset
WO2004035034A3 (en)	2004-07-22	Clofarabine and taxane chemotherapy combination
AU2002320653B2 (en)	2007-09-27	Stent graft with branch leg